- Valbenazine Met the Primary Endpoint of Significant (p<0.0001) Improvement in Chorea Severity versus Placebo as Measured by the Unified Huntington's Disease Rating Scale (UHDRS®) Total Maximal...

Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic NEW YORK,

Shulman Rogers, a full-service law firm located in the Washington, D.C. Metropolitan area, is proudly celebrating its 50th anniversary. Founded by Larry Shulman in 1972, with Don Rogers joining a...

Foot Locker, Inc. (NYSE: FL), the New York-based specialty athletic retailer, today announced that Richard Johnson, Chairman and Chief Executive Officer, and Andrew Page, Executive Vice President...

Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive...